Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$733.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Margaret Alexander
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 23
- Beta
- 0.25
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 10.02
Financials
Revenue
$733.0K-89.4%Net Income
$-15.01MEBITDA
$-15.38MFree Cash Flow
$-17.59MEPS (diluted)
$-0.20Shares Outstanding (diluted)
73.74M+276.2%Operating Expenses
$16.13MCash & Debt
$117.22MRevenue by Segment (annual)
$7.25MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $7.25M | $-17.41M | $-0.24 |
| 2024 | $566.0K | $-26.43M | $-0.37 |
| 2023 | $392.0K | $-52.34M | $-0.74 |
| 2022 | $1.50M | $-54.17M | $-0.77 |
| 2021 | $208.38M | $122.83M | $1.78 |
| 2020 | $12.62M | $-81.04M | $-1.39 |
| 2019 | $0.00 | $-60.46M | $-1.51 |
| 2018 | $0.00 | $-51.98M | $-2.11 |
| 2017 | $0.00 | $-64.81M | $-3.35 |
| 2016 | $0.00 | $-22.41M | $-1.14 |
| 2015 | $0.00 | $-13.16M | $-0.67 |
| 2014 | $0.00 | $-447.0K | $-0.09 |
Valuation
OVIDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-54.35%Social Signal Score
Mentions (3)
- Newszacks.com·48d ago·Positive
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now? Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newszacks.com·53d ago·Neutral
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates Ovid Therapeutics (OVID) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.06 per share a year ago.
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including financial results for the second quarter ended June 30, 2026.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.08 per share
Typical surprise +18.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.08 vs $-0.12beat
- Tue, May 12$-0.12 vs $-0.12beat
- Wed, Mar 18$0.06 vs $-0.10beat
- Wed, Nov 12$-0.17 vs $-0.15miss
- Wed, Aug 13$-0.06 vs $-0.16beat
- Tue, May 13$-0.14 vs $-0.14beat
Estimates and results for OVID via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by OVID officers and directors.
- Bought
- $171k
- Sold
- $72k
5 trades
5 trades
- Alexander Margaret A.sold
- Rona Jeffrey Asold
- Levin Jeremy Mbought
- Levin Jeremy Mbought
- Levin Jeremy Mbought
- Alexander Margaret A.sold
- Rona Jeffrey Asold
- Alexander Margaret A.bought
90 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in OVID.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.